Plain-English translation of NCT06419374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called in people who have advanced fatty liver disease with cirrhosis. Cirrhosis happens when the liver becomes scarred and damaged, often from fat buildup. Researchers want to see if this medication can help slow or improve liver disease in people whose livers are still functioning at a basic level.
Currently, there are few treatment options for people with advanced fatty liver disease and cirrhosis. This trial exists to find out whether the medication can help protect the liver and prevent the disease from getting worse.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either or a placebo (a dummy medication that looks identical but has no active ingredient) — you and the researchers won't know which one you're getting. You'll need to visit the clinic regularly for check-ups, blood tests, and imaging scans to monitor your liver health. The study will track your progress over time to see if the medication helps slow liver damage.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States